RAVE
Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis
Paciente / Población Intervención / Exposición Comparación Desenlace
In 197 patients with severe ANCA-associated vasculitis, rituximab was non-inferior for inducing remission compared with cyclophosphamide.
N
197
Diseño
Double-blind, double-dummy RCT
Desenlace
Complete remission without steroids at month 6
Relevancia
1
ResultadoRituximab 64% vs cyclophosphamide 53% (non-inferior); superior in the relapsing subgroup.
Stone JH, et al. N Engl J Med. 2010;363(3):221-232. 10.1056/NEJMoa0909905
Discusión y crítica
Established rituximab as standard induction in ANCA vasculitis, sparing cyclophosphamide exposure.